



## RATHINDRA N. BOSE

Vice Chancellor for Research and Technology Transfer, University of Houston System  
Vice President for Research and Technology Transfer, University of Houston


### PREAMBLE

I am honored to testify on the subject of accelerating technology transfer to the marketplace, a key component in furthering economic development within the State of Texas.

The University of Houston is poised to become a national leader in translational research and technology transfer. UH has developed a strategic plan and created the Energy Research Park (ERP), a 74-acre site designed to foster and accelerate research development, commercialization, and manufacturing of UH-discovered technologies.

### UH INITIATIVE

The University of Houston, a Carnegie-designated Tier One research institution, has initiated a strategic plan to aggressively promote technology commercialization and economic development. UH is creating and assisting existing spin-off companies as well as expanding partnerships within the business community. With 300 patents issued or pending, the university is actively innovating numerous commercially viable technologies.



# STRATEGIC GOALS

## \$50M Royalty/Licensing Income by 2020 200 Employees in Energy Research Park \$200M Research Expenditures

### 1 Aggressively commercialize technology

Recruit manufacturing companies in the Energy Research Park  
Create a true incubator with executives-in-residence to help faculty create companies  
Partner with Texas-based companies to jointly develop technologies

2

### 2 Increase royalty income

2012 royalty income of \$13M from 26 products  
2013 projected increase to \$15M

3

### 3 Invest in STEM fields

Recruit 60 new STEM faculty in 2013

4

### 4 Create infrastructure


Build new research core facilities

5

### 5 Increase funding


Federal and private sources

### Royalty Income: Six-Year Trend



# UH BREAKTHROUGH TECHNOLOGY EXAMPLES

## Lacosamide (Vimpat)—Anti-Epileptic Drug



Veronica Crowe, an epilepsy patient who has been seizure-free using lacosamide

- Over \$300 million sales as adjunctive therapy in 2012
- Over 200,000 patients successfully treated
- Approved in 34 countries for treating partial-onset seizures
- 3 clinical trials underway testing compound
- Plans to expand applications
- Estimated market value of \$2B per annum

## Second Generation High Temperature Superconductors (2G-HTS)

